ArticleFEBS open bio2022

Corrigendum to: Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.